ClinicalTrials.gg
CompletedNCT00995293Updated Mar 2, 2018

Taxotere (Docetaxel) New Indication: Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treatment Registration Trial

A Phase 3 interventional study of DOCETAXEL and CISPLATIN in Head and Neck Neoplasms, sponsored by Sanofi. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-03-02.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies testing cisplatin in Head and Neck Neoplasms — 11 open to participants now, 18 under way, 1 of them phase 3. Cisplatin · Head and Neck Neoplasms.

Enrollment
10th of 119
240 · median 42
Started
2009
with 5 others
Phase 3
11 of 127
none open now
Registered
72nd of 127
by date
Lead sponsor
4 of 127
Sanofi

Among the 127 studies testing cisplatin in Head and Neck Neoplasms, this one is the 10th largest by enrollment of the 119 interventional ones that give a count, is one of 6 that started in 2009, is one of 11 in phase 3, and was the 72nd registered.

Head and Neck Neoplasms

2,714 studies on the registry are indexed under Head and Neck Neoplasms; 597 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

11 of the 127 studies testing cisplatin in Head and Neck Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About cisplatin

Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 456 Head and Neck Neoplasms studies recruiting now, 348 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies testing cisplatin in Head and Neck Neoplasms, or all of them as a file.
02

Study summary

The Primary Objective is to evaluate the progression-free survival after treatment with docetaxel plus cisplatin plus 5-Fluorouracil (5-FU) (DCF) in comparison with cisplatin plus 5-FU (CF) in patient with locally advanced inoperable SCCHN The Secondary Objective is to evaluate and compare the clinical response rate both before and after radiotherapy, the local symptoms, the duration of response, the time to treatment failure, the survival, the toxicity and the quality of life in the 2 study groups.

03

Conditions studied

  • Head and Neck Neoplasms
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Tumor type: or cytologically proven squamous cell carcinoma of the head and neck (SCCHN) presenting with locally advanced disease at diagnosis. Primary tumor sites eligible are: oral cavity, oropharynx, hypopharynx and larynx.
  • Extent of the disease:

    • Patients are required to have at least one .
    • Stage III or IV without evidence of distant , according to the TNM staging system. Absence of metastases must be checked by chest X-ray (with or without Computed tomography (CT) ), abdominal ultrasound or CT in case of liver function test abnormalities, and bone scan in case of local symptoms.
    • Tumor considered as inoperable after evaluation by a multidisciplinary team. Reason for inoperability will be reported in the CRF
  • World Health Organization (WHO) performance status 0 or 1
  • Laboratory data:

    • Haematology:
  • > or = 2.0*10\^9/L
  • count > or = 100*10\^9/L
  • > or = 10 g/dl (6.2 mmol/L)

    • Hepatic function:
  • Total serum \< or = 1 time the upper normal limit (UNL) of the participating center
  • (ASAT/SGOT) and Alanine transaminase (ALAT/SGPT) \< or = 2.5UNL
  • Alkaline phosphatase \< or = 5 UNL
  • Patients with ASAT or ALAT > 1.5UNL associated with alkaline phosphatase >2.5UNL are not eligible for the study

    • Renal function:
  • serum creatinine \< or = 120µmol/L (1.4 mg/dl) if values are >120µmol/L, should be > or = 60 ml/min
  • Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule, those conditions should be discussed with the patient before registration in the trial
  • Patients form obtained

Exclusion criteria

Exclusion criteria:

  • Tumors of the nasopharynx, the nasal and paranasal cavities.
  • Previous chemotherapy or radiotherapy for any reason and previous surgery for SCCHN at time of study entry.
  • Prior treatment within a therapeutic clinical tria within 30 days prior to study entry
  • Concurrent treatment with any other anticancer therapy
  • Chronic treatment (> or = 3 months) with at a daily dose > or = 20mg methylprednisolone or equivalent.
  • Concomitant use of drugs which could interact with 5-fluorouracil (e.g. cimetidine, allopurinol, folic or folinic acid, methotrexate and metronidazole)
  • Previous or current at other sites with the exception of adequately treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma of the skin or other cancer curatively treated by surgery and with no evidence of disease for at least 5 years
  • Symptomatic peripheral neuropathy > or = grade 2 by NCIC-CTG criteria
  • Clinical altered hearing
  • Pregnant, lactating women or of unless adequate
  • with other serious illness or medical condition including but not limited to:

    • unstable cardiac disease despite treatment
    • myocardial infarction within 6 months prior to study entry
    • history of significant neurologic or psychiatric disorders including dementia or seizures
    • active uncontrolled infection
    • active peptic ulcer
    • requiring hospitalization during the year preceding study entry

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (actual)

Study arms

  • Experimental
    Docetaxel Cisplatin 5-Fluorouracil (DCF)

    4 cycles of the following products every 3 weeks (unless disease progression/relapse or unacceptable toxicity occured or the patient refused treatment): * Docetaxel 60mg/m² on day 1 * Cisplatin 75mg/m² on day 1 * 5-FU 750mg/m²/day on day 1 to day 5

    Drug: DOCETAXEL · Drug: CISPLATIN · Drug: 5-FLUOROURACIL

  • Experimental
    Cisplatin 5-Fluorouracil (CF)

    4 cycles of the following products every 3 weeks (unless disease progression/relapse or unacceptable toxicity occured or the patient refused treatment): * Cisplatin 75mg/m² on day 1 * 5-FU 750mg/m²/day on day 1 to day 5

    Drug: CISPLATIN · Drug: 5-FLUOROURACIL

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-free survival

    Time frame: From randomization to any progression event or patient death (follow-up every 3 months 1st year, then every 6 months)

Secondary outcomes

  1. Overall survival

    Time frame: From randomization to patient death (follow-up every 3 months 1st year, then every 6 months)

  2. Overall response rates

    Time frame: From randomization to any progression event or patient death (follow-up every 3 months 1st year, then every 6 months) and at the end of chemotherapy + end of radiotherapy

  3. Duration of response

    Time frame: From randomization to any progression event or patient death (follow-up every 3 months 1st year, then every 6 months)

  4. Time to treatment failure

    Time frame: From randomization to any progression event or patient death (follow-up every 3 months 1st year, then every 6 months) and at the end of chemotherapy + end of radiotherapy

07

Study locations

1 site
  • Sanofi Administrative Office
    Shanghai, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2009 to primary completion in Jan 2018, 100 months.

Of 66 phase 3 interventional studies under Head and Neck Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 100. This study's 100 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2009
First posted
Oct 15, 2009
StartActual
Aug 27, 2009
Primary completionActual
Jan 26, 2018
CompletionActual
Jan 26, 2018
Last update
Mar 2, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00995293
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Oct 15, 2009
Start date
Aug 27, 2009
Primary completion
Jan 26, 2018
Completion
Jan 26, 2018
Last update
Mar 2, 2018

Study contacts

Mo Chen
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cisplatin · Fluorouracil

Start the discussion